Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 118, Issue -, Pages 2-7Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2017.09.009
Keywords
Cancer; Antigen; Antibody; Enzyme; Immunogenicity; Prodrug; Clinical trials
Categories
Funding
- Cancer Research UK
- Post Natal Choriocarcinoma Trust
- Royal Free Cancer Research Trust
- AstraZeneca
- National Translational Cancer Research Network
Ask authors/readers for more resources
Antibody directed enzyme prodrug therapy has the potential to be an effective therapy for most common solid cancers. Clinical studies with CPG2 system have shown the feasibility of this approach. The key limitation has been immunogenicity of the enzyme. Technologies now exist to eliminate this problem. Non-immunogenic enzymes in combination with prodrugs that generate potent cytotoxic drugs can provide a powerful approach to cancer therapy. ADEPT has the potential to be non-toxic to normal tissue and can therefore be combined with other modalities including immunotherapy for greater clinical benefit. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available